Glyco-gene expression in human breast cancer MDA-MB-231 cells treated with ManNAc analogs
Ontology highlight
ABSTRACT: Analogs of ManNAc, the committed precursor of sialic acid, decrease metastatic potential and trigger apoptosis in cancer cells. Adding Lev to ManNAc analogs increases their toxicity due to an ill-understood mechanism. Comparing gene expression profiles of cells treated with Ac4ManNLev and Ac4ManNAc will provide insight into the similarities and differences of these analogs. Specifically, MDA-MB-231 human breast cancer cells will be treated with Ac4ManNLev and Ac4ManNAc at doses that inhibit cell growth and induce the cell to undergo apoptosis later. RNA will be harvested in the early stage of cell arrest in order to identify genes altered by Ac4ManNLev and Ac4ManNAc.
ORGANISM(S): Homo sapiens
PROVIDER: GSE28939 | GEO | 2011/04/29
SECONDARY ACCESSION(S): PRJNA139897
REPOSITORIES: GEO
ACCESS DATA